1. Placebo Harm

   • I. Ralph Edwards
   • Joe Graedon
   • Terry Graedon

   Editorial 21 November 2012 Pages: 439 - 441

2. Identification of NSAID Users at Risk for Gastrointestinal Complications

   • Merel M. Tielemans
   • Ties Eikendal
   • Martijn G. H. van Oijen

   Review Article 21 November 2012 Pages: 443 - 453

   

3. Benefit-Risk Assessment of Becaplermin in the Treatment of Diabetic Foot Ulcers

   • DrNikolaos Papanas
   • Efstratios Maltezos

   Review Article 21 November 2012 Pages: 455 - 461

4. A Decade of Safety-Related Regulatory Action in the Netherlands

   • Peter G.M. Mol
   • Sabine M. J. M. Straus
   • Flora M. Haaijer-Ruskamp

   Original Research Article 21 November 2012 Pages: 463 - 474

   

5. Validation of Statistical Signal Detection Procedures in EudraVigilance Post-Authorization Data

   • Yolanda Alvarez
   • Ana Hidalgo
   • Jim Slattery

   Original Research Article 21 November 2012 Pages: 475 - 487

   

6. Infliximab Paediatric Crohn’s Disease Educational Plan

   • Alejandro Arana
   • Sam Allen
   • Felix M. Arellano

   Original Research Article 21 November 2012 Pages: 489 - 501

   

7. Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase™

   • Ayako Suzuki
   • Raul J. Andrade
   • James W. Freston

   Original Research Article 21 November 2012 Pages: 503 - 522

   

8. Leflunomide in Combination Therapy for Rheumatoid Arthritis

   • Ruth L. Savage

   Commentary 21 November 2012 Pages: 523 - 526